The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Spontaneous and inherited TP53 genetic alterations
Abstract
The p53 protein is a transcription factor that prevents tumors from developing. In spontaneous and inherited cancers there are many different missense mutations in the DNA binding domain of the TP53 gene that contributes to tumor formation. These mutations produce a wide distribution in the transcriptional capabilities of the mutant p53 proteins with over four logs differences in the efficiencies of forming cancers in many diverse tissue types. These inherited and spontaneous TP53 mutations produce proteins that interact with both genetic and epigenetic cellular modifiers of p53 function and their inherited polymorphisms to produce a large number of diverse phenotypes in individual patients. This manuscript reviews these variables and discusses how the combinations of TP53 genetic alterations interact with genetic polymorphisms, epigenetic alterations, and environmental factors to begin predicting and modifying patient outcomes and provide a better understanding for new therapeutic opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TP53 is the most frequently mutated gene in human malignancies, 50% of which carry alterations to it.”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [7]
In the citing paper
“TP53 is the most frequently mutated gene in human malignancies, 50% of which carry alterations to it.”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“MDM2 SNP309 (rs2279744) polymorphism (a T to G change in the promoter/enhancer region of the MDM-2 gene) The MDM-2 protein is the major E-3 ubiquitin ligase for the regulation and degradation of the p53 protein [53].”
BackgroundThe p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Self-citationHigh burden and pervasive positive selection of somatic mutations in normal human skin
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. C., Fullam, A., Alexandrov, L. B., Tubio, J. M., et al. (2015) · Science · doi:10.1126/science.aaa6806 · Cited by 1,770
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 1×
“When this was done with cells containing a temperaturesensitive mutant p53, at the non-permissive temperature (p53 inactive), the transcription factors c-Myc and Klf-4 could be eliminated and the percentage of IPSC produced went up as high as 80% and the kinetics of producing IPSC occurred in days, not weeks or months…”
BackgroundBond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citationThe IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Clonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156 · cited 1×
“Although these prevalence estimates are dynamically altered based on variable mutation classifications and highly impacted by some specific controvertible spontaneous TP53 mutations, the databases employed could introduce other possible biases, such as CHIP, or enrichment of mutations potentially associated with lower…”
BackgroundLandscape of X chromosome inactivation across human tissues
GTEx Consortium, Tukiainen, T., Villani, A.-C., Yen, A., Rivas, M. A., Marshall, J. L., Satija, R., Aguirre, M., Gauthier, L., Fleharty, M., et al. (2017) · Nature · doi:10.1038/nature24265 · Cited by 1,138
Research works printed but not linked: 50
- Weissman I. Stem cells are units of natural selection for tissue formation for germline development and cancer development. Proc Natl Acad Sci USA. 2015;112:8922–8. · DOI
- Blancpain C, Fuchs E. Epidermal stem cells of the skin. Annu Rev Cell Developmental Biol. 2006;22:339–73. · DOI · Paper page
- Barker N, Tan S, Clevers H. Lgr proteins in epithelial stem cell biology. Development 2013;140:2484–94. https://doi.org/10.1242/dev.083113. · DOI
- Dubrovsky G, Dunn JCY. Mechanisms for intestinal regeneration. Curr. Opin Pediatrics. 2018;30:424–9. · DOI
- Takeo M, Lee W, Ito M. Wound healing and skin regeneration. Cold Spring Harb Perspect Med. 2015;5:a023267. · DOI · Paper page
- Levine AJ. 2020. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471–80. https://doi.org/10.1038/s41568-020-0262-1. · DOI · Paper page
- Cancer Genome Atlas Research Network WeinsteinJN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113–20. · DOI · Paper page
- Haigis KM, Cichowski K, Elledge SJ. Tissue- specificity in cancer: the rule, not the exception. Science. 2019;363:1150–1. · DOI · Paper page
- Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, et al. Ultra- sensitive TP53 sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan. Cell Rep. 2019;28:132–44. · DOI · Paper page
- Williams MJ, Zapata L, Werner B, Barnes CP, Sottoriva A, Graham TA. Measuring the distribution of fitness effects in somatic evolution by combining clonal dynamics with dN/dS ratios. Elife. 2020;9:e48714. https://doi.org/10.7554/eLife.48714. PMID: 32223898; PMCID: PMC7105384 · DOI
- Silver AJ, Jaiswal S. Clonal hematopoiesis: pre- cancer PLUS. Adv Canc Res. 2019;141:85–128. · DOI
- Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild- type p53. Science. 1990;249:912–5. · DOI · Paper page
- Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–22.
- Takeda H, Wei Z, Koso H, Rust AG, Yew CC, Mann MB, et al. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 2015;47:142–50. · DOI
- Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6:a026179. · DOI · Paper page
- Levine AJ, Chan CS, Dudgeon C, Puzio-Kuter A, Hainaut P. The evolution of tumors in mice and humans with germline p53 mutations. Cold Spring Harb Symp Quant Biol. 2015;80:139–45. · DOI
- Amadou A, Achatz MW, Hainaut P. Revisiting tumor patterns and penetrance in germline Tp53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30:23–29. · DOI · Paper page
- Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994;8:1235–1246. · DOI · Paper page
- Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72. https://doi.org/10.1016/j.ceb.2017.11.005. ()e-pub ahead of print 2017 Nov 28. PMID: 29195118; PMCID: PMC5949255. · DOI · Paper page
- Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 1996;93:15335–40. https://doi.org/10.1073/pnas.93.26.15335. PMID: 8986812; PMCID: PMC26405. · DOI · Paper page
- Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21:9–21. https://doi.org/10.1038/sj.onc.1205015. PMID: 11791172 · DOI
- Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;154–60. https://doi.org/10.1038/cdd.2017.180. e-pub 2017 Nov 3. PMID: 29099487; PMCID: PMC5729536. · DOI · Paper page
- Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:1498–502. https://doi.org/10.1126/science.7878469. PMID:7878469 · DOI · Paper page
- Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, et al. XAF1 as a modifier of p53 function and cancer susceptibility. Sci Adv. 2020;6:eaba3231 https://doi.org/10.1126/sciadv.aba3231. PMID: 32637605; PMCID: PMC7314530 · DOI
- Levine AJ, Berger SL. The interplay between epigenetic changes and the p53 protein in stem cells. Genes Dev 2017;31:1195–201. https://doi.org/10.1101/gad.298984.117. PMID: 28765161; PMCID: PMC5558922. · DOI
- Zhu J, Dou Z, Sammons MA, Levine AJ, Berger SL. Lysine methylation represses p53 activity in teratocarcinoma cancer cells. Proc Natl Acad Sci USA 2016;113:9822–7. https://doi.org/10.1073/pnas.1610387113. PMID: 27535933; PMCID: PMC5024588. · DOI
- de Andrade KC, Mirabello L, Stewart DR, Karlins E, Koster R, Wang M, et al. Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat 2017;38:1723–30. https://doi.org/10.1002/humu.23320. PMID: 28861920; PMCID: PMC6858060. · DOI
- de Andrade KC, Frone MN, Wegman-Ostrosky T, Khincha PP, Kim J, Amadou A, et al. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis. Hum Mutat 2019;40:97–105. https://doi.org/10.1002/humu.23673. PMID: 30352134; PMCID: PMC6296902. · DOI
- Barnoud T, Parris JLD, Murphy M. Common Genetic Variants in the Tp53 Pathway and their impact on Cancer. Jour Mol Cell Biol. 2019;11:578–85. · DOI
- Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3:128–33. https://doi.org/10.1038/35055027. PMID: 11175744 · DOI · Paper page
- Jeong SI, Kim JW, Ko KP, Ryu BK, Lee MG, Kim HJ, et al. XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis. Cell Death Dis 2018;9:806. https://doi.org/10.1038/s41419-018-0867-4. PMID: 30042418; PMCID: PMC6057933. · DOI
- Victoria-Acosta G, Vazquez-Santillan K, Jimenez-Hernandez L, Munoz-Galindo L, Maldonado V, Martinez-Ruiz GU, et al. Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep. 2015;5:14838 https://doi.org/10.1038/srep14838 · DOI
- Lee MG, Han J, Jeong SI, Her NG, Lee JH, Ha TK, et al. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. Proc Natl Acad Sci Usa 2014;111:15532–7. https://doi.org/10.1073/pnas.1411746111. PMID: 25313037; PMCID: PMC4217407. · DOI
- Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016;30:918–30. https://doi.org/10.1101/gad.275891.115. 2016PMID: 27034505; PMCID: PMC4840298. · DOI · Paper page
- Singh KS, Leu JI, Barnoud T, Vonteddu P, Gnanapradeepan K, Lin C, et al. African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin. Nat Commun 2020;11:473 https://doi.org/10.1038/s41467-019-14151-9. Erratum in: Nat Commun. 2020 Mar 19;11(1):1541. PMID: 31980600; PMCID: PMC6981190.. · DOI
- Murphy ME, Liu S, Yao S, Huo D, Liu Q, Dolfi SC, et al. A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer. 2017; 3:5. https://doi.org/10.1038/s41523-017-0007-9. PMID: 28649645; PMCID: PMC5445618. · DOI
- Barnoud T, Budina-Kolomets A, Basu S, Leu JI, Good M, Kung CP, et al. Tailoring chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 2018;78:5694–705. https://doi.org/10.1158/0008-5472.CAN-18-1327. PMID: 30115697; PMCID: PMC6168343. · DOI
- Gnanapradeepan K, Leu JI, Basu S, Barnoud T, Good M, Lee JV, et al. Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser. Elife. 2020;10:9–e55994. https://doi.org/10.7554/eLife.55994. NovPMID: 33170774; PMCID: PMC7661039 · DOI
- Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65. https://doi.org/10.1038/ng1093. PMID: 12567188 · DOI · Paper page
- Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011;43:1098–103. https://doi.org/10.1038/ng.926. PMID: 21946351; PMCID: PMC3263694 · DOI · Paper page
- Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A, et al. The origins and evolution of the p53 family of genes. The P53 Family: Chapter 1, Cold Spring Harbor Perspectives in Biology. Cold Spring Harbor Laboratory Press; 2010. · DOI · Paper page
- Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande, Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744–7. https://doi.org/10.1126/science.271.5256.1744. PMID: 8596939 · DOI · Paper page
- Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet. 2001;27:31–9. https://doi.org/10.1038/83730. PMID: 11137995. · DOI · Paper page
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–76. https://doi.org/10.1016/j.cell.2006.07.024. PMID: 16904174 · DOI · Paper page
- Yi L, Lu C, Hu W, Sun Y, Levine AJ Multiple roles of p53 related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res 2012; 72: 5635-45. PMCID: PMC3494373 · DOI
- Yi L, Y Sun, Levine AJ. Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget. 2014;5:8924–36. https://doi.org/10.18632/oncotarget.2441. PMCID:PMC4253407 · DOI
- Horvath S, Gurven M, Levine ME, Trumble BC, Kaplan H, Allayee H, et al. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol. 2016;17:171 https://doi.org/10.1186/s13059-016-1030-0. PMID: 27511193; PMCID: PMC4980791 · DOI · Paper page
- Harmeyer KM, Facompre ND, Herlyn M, Basu D. JARID1 histone demethylases: emerging targets in cancer. Trends Cancer 2017;3:713–25. https://doi.org/10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12. PMID: 28958389; PMCID: PMC5679451 · DOI
- Mizukami H, Kim JD, Tabara S, Lu W, Kwon C.Nakashima M,et al. KDM5D-mediated H3K4 demethylation is required for sexually dimorphic gene expression in mouse embryonic fibroblasts. J Biochem. 2019;165:335–42. https://doi.org/10.1093/jb/mvy106. PMID: 30541083. · DOI
- Hu D, Jablonowski C, Cheng PH, AlTahan A, Li C, Wang Y, et al. KDM5A regulates a translational program that controls p53 protein expression. iScience 2018;9:84–100. https://doi.org/10.1016/j.isci.2018.10.012. Nov 30 Epub 2018 Oct 17. PMID: 30388705; PMCID: PMC6214872 · DOI
Cited by
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Metadata
- Authors
- Levine, A. J.
- ORCID
- Levine, Arnold J.
- Venue
- Oncogene
- Published
- 2021-08-13
- Volume
- 40
- Issue
- 41
- Pages
- 5975-5983
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 59
- References
- 20
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (PO1 CA087497)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spontaneous and inherited TP53 genetic alterations. https://app.cochat.ai/papers/10.1038/s41388-021-01991-3
- The paper
- Levine, A. J. (2021). Spontaneous and inherited TP53 genetic alterations. Oncogene. https://doi.org/10.1038/s41388-021-01991-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.